1-methylxanthine-based bioactive composition and method of use thereof
The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises 1-methylxanthine and optionally other compounds that modulate the effects of 1-methylxanthine. Uses for the 1-methylxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.
1. A method for increasing energy in a subject comprising administering to the subject a composition comprising an effective amount of 1-methylxanthine, wherein the amount of 1-methylxanthine administered is from about 50 mg to about 400 mg.
2. The method of claim 1 , wherein the subject experiences an increase in perception of energy of at least about 5%.
3. The method of claim 1 , wherein the subject experiences a decrease of at least one of anxiety, fatigue, perception of effort, and/or perception of pain.
4. The method of claim 1 , wherein the composition further comprises paraxanthine in an amount from about 2 mg to about 800 mg.
5. The method of claim 4 , wherein the administration of paraxanthine and 1-methylxanthine produces a synergistic increase in perception of energy in the subject, relative to the administration of a comparable dose of paraxanthine or 1-methylxanthine alone.
6. The method of claim 1 , wherein the composition further comprises at least one ingredient selected from the group consisting of L-theanine, phosphatidylcholine, alpha-GPC (L-alpha glycerylphosphorylcholine), Citicoline (Cytidine diphosphate choline (CPD Choline)), Choline Bitartrate, Bacopa monnieri , Phosphatidylserine, pilocarpine, and cevimeline Amburana cearensis, Lippia sidoides, Paullinia cupana, Plathymiscium floribundum , tetrahydrocurcumin, and Solanum asperum and/or combinations thereof, caffeine, theobromine, naringin, hesperidin, 2-(dimethylamino) ethanol (DMAE), DMAE bitartrate, Magnolia bark, theanine, phosphatidylserine, ashwagandha, Rhodiola , taurine, tyrosine, n-acetyl-tyrosine, macuna, Sceletium tortuosa, 5-HTP, tryptophan, saffron, Vitamin D, SAMe, lions mane and huperzine A.
7. The method of claim 1 , wherein the composition is substantially free of caffeine.
8. A method for improving athletic performance in a subject in comprising administering to the subject a composition comprising an effective amount of 1-methylxanthine wherein the amount of 1-methylxanthine administered is from about 50 mg to about 400 mg and wherein the amount of paraxanthine is administered is from about 2 mg to about 800 mg.
9. The method of claim 8 , wherein athletic performance is increased by at least about 10%.
10. The method of claim 8 , wherein the subject experiences an increase in endurance.
11. The method of claim 8 , wherein the composition further comprises paraxanthine in an amount from about 50 mg to about 400 mg and wherein administration of the composition to a subject produces a synergistic increase in athletic performance, relative to the administration of a comparable dose of paraxanthine or 1-methylxanthine alone.
12. The method of claim 8 , wherein the composition further comprises at least one agent selected from the group consisting of L-theanine, phosphatidylcholine, alpha-GPC (L-alpha glycerylphosphorylcholine), Citicoline (Cytidine diphosphate choline (CPD Choline)), Choline Bitartrate, Bacopa monnieri , Phosphatidylserine, pilocarpine, and cevimeline Amburana cearensis, Lippia sidoides, Paullinia cupana, Plathymiscium floribundum , tetrahydrocurcumin, and Solanum asperum and/or combinations thereof, caffeine, theobromine, naringin, hesperidin, 2-(dimethylamino) ethanol (DMAE), DMAE bitartrate, huperzine A, theacrine, methylliberine, B12, sulbutiamine, Magnolia bark, ketones, MCTs, omega 3's, lutein, zeaxanthin, tyrosine and n-acetyl-tyrosine, taurine, acetyl-1-carnitine and/or combinations thereof.
13. A method for increasing energy in a subject comprising administering to the subject a composition comprising an effective amount of 1-methylxanthine and paraxanthine, wherein the amount of 1-methylxanthine administered is from about 50 mg to about 400 mg and wherein the amount of paraxanthine is administered is from about 50 mg to about 400 mg wherein the administration of paraxanthine and 1-methylxanthine produce a synergistic increase in perception of energy in the subject, relative to the administration of a comparable dose of paraxanthine or 1-methylxanthine alone.